Research graph
References from Differential kinetics of SARS-CoV-2 proteases revealed by a two-color, BRET-based dual protease biosensor, DuProSense. Local targets link to admitted publications; unresolved targets remain external evidence.
The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
10.1038/s41467-022-28354-0 · 2022 · External reference
A slow but steady nanoLuc: R162A mutation results in a decreased, but stable, nanoLuc activity
10.1016/j.ijbiomac.2024.131864 · 2024 · External reference
Coevolving residues distant from the ligand binding site are involved in GAF domain function
10.1038/s42004-025-01447-9 · 2025 · External reference
Coevolving residues distant from the ligand binding site are involved in GAF domain function
10.1038/s42004-025-01447-9 · 2025 · External reference
Intracellular ionic strength sensing using NanoLuc
10.3390/ijms22020677 · 2021 · External reference
The BRET technology and its application to screening assays
10.1002/biot.200700222 · 2008 · External reference
Programmed ribosomal frameshifting in decoding the SARS-CoV genome
10.1016/j.virol.2004.11.038 · 2005 · External reference
mScarlet: a bright monomeric red fluorescent protein for cellular imaging
10.1038/nmeth.4074 · 2017 · External reference
A coarse-grained model for disordered and multi-domain proteins
2024 · External reference
Discovery of SARS-CoV-2 M(pro) peptide inhibitors from modelling substrate and ligand binding
10.1039/d1sc03628a · 2021 · External reference
Substrate recognition and selectivity in SARS-CoV-2 main protease: unveiling the role of subsite interactions through dynamical nonequilibrium molecular dynamics simulations
2023 · External reference
Impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant-associated receptor binding domain (RBD) mutations on the susceptibility to serum antibodies elicited by coronavirus disease 2019 (COVID-19) infection or vaccination
10.1093/cid/ciab656 · 2022 · External reference
Residues on the dimer interface of SARS coronavirus 3C-like protease: dimer stability characterization and enzyme catalytic activity analysis
10.1093/jb/mvm246 · 2008 · External reference
A bright cyan-excitable Orange fluorescent protein facilitates dual-emission microscopy and enhances bioluminescence imaging in vivo
10.1038/nbt.3550 · 2016 · External reference
A genetically encoded IL-1β bioluminescence resonance energy transfer sensor to monitor inflammasome activity
10.4049/jimmunol.1201349 · 2012 · External reference
Bioluminescence resonance energy transfer biosensor for measuring activity of a protease secreted by Pseudomonas fluorescens growing in milk
10.1016/j.aca.2023.341401 · 2023 · External reference
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
10.1126/science.abb4489 · 2020 · External reference
Evolution of BRET biosensors from live cell to tissue-scale in vivo imaging
10.3389/fendo.2013.00131 · 2013 · External reference
Bright bioluminescent BRET sensor proteins for measuring intracellular caspase activity
10.1021/acssensors.7b00239 · 2017 · External reference
Chai-1: decoding the molecular interactions of life
2024 · External reference
NanoLuc: a small luciferase is brightening up the field of bioluminescence
10.1021/acs.bioconjchem.6b00112 · 2016 · External reference
The coding capacity of SARS-CoV-2
10.1038/s41586-020-2739-1 · 2021 · External reference
Allostery in homodimeric SARS-CoV-2 main protease
10.1038/s42003-024-07138-w · 2024 · External reference
Development of a fluorescence-based, high-throughput SARS-CoV-2 3CLpro reporter assay
10.1128/jvi.01265-20 · 2020 · External reference
Both boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
10.1038/s41467-020-18233-x · 2020 · External reference
The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery
10.1038/s41467-020-20718-8 · 2021 · External reference
Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model
10.1126/sciadv.ado4288 · 2024 · External reference
A genetically encoded BRET-based SARS-CoV-2 Mpro protease activity sensor
10.1038/s42004-022-00731-2 · 2022 · External reference
Dynamics of huntingtin protein interactions in the striatum identifies candidate modifiers of huntington disease
10.1016/j.cels.2022.01.005 · 2022 · External reference
Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): expression, purification, characterization, and inhibition
10.1021/bi0504761 · 2005 · External reference
SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
10.1016/s2666-5247(21)00068-9 · 2021 · External reference
Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway
10.1074/jbc.m609695200 · 2007 · External reference
Kinetic comparison of all eleven viral polyprotein cleavage site processing events by SARS-CoV-2 main protease using a linked protein FRET platform
10.1016/j.jbc.2024.107367 · 2024 · External reference
Creation of artificial luciferases for bioassays
10.1021/bc400411h · 2013 · External reference
Kinetic characterization and inhibitor screening for the proteases leading to identification of drugs against SARS-CoV-2
10.1128/aac.02577-20 · 2021 · External reference
X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation
10.1038/s41467-022-32854-4 · 2022 · External reference
Improved SARS-CoV-2 main protease high-throughput screening assay using a 5-carboxyfluorescein substrate
10.1016/j.jbc.2022.101739 · 2022 · External reference
Development of conformational BRET biosensors that monitor ezrin, radixin and moesin activation in real time
10.1242/jcs.255307 · 2021 · External reference
Distal protein-protein interactions contribute to nirmatrelvir resistance
10.1038/s41467-025-56651-x · 2025 · External reference
Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
10.1016/s1473-3099(23)00118-4 · 2023 · External reference
Investigation of small molecule inhibitors of the SARS-CoV-2 papain-like protease by all-atom microsecond modelling, PELE monte carlo simulations, and in vitro activity inhibition
10.1016/j.cplett.2021.139294 · 2022 · External reference
Consensus guided mutagenesis of renilla luciferase yields enhanced stability and light output
10.1093/protein/gzl023 · 2006 · External reference
Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19
10.1038/s41467-024-54462-0 · 2024 · External reference
Identification of human host substrates of the SARS-CoV-2 M(pro) and PL(pro) using subtiligase N-Terminomics
10.1021/acsinfecdis.2c00458 · 2023 · External reference
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
10.1038/s41422-020-0356-z · 2020 · External reference
Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-Based reporter assay
10.1021/acscentsci.1c00519 · 2021 · External reference
Validation and invalidation of SARS-CoV-2 main protease inhibitors using the Flip-GFP and protease-glo luciferase assays
2021 · External reference
Exploring nirmatrelvir derivatives through P2 substituent modifications and warhead innovations targeting the main protease of SARS-CoV-2
10.1002/ardp.70158 · 2025 · External reference
Paxlovid: mechanism of action, synthesis, and in Silico Study
10.1155/2022/7341493 · 2022 · External reference
A SARS-CoV-2 Mpro mutation conferring ensitrelvir resistance paradoxically increases nirmatrelvir susceptibility
10.1038/s41467-025-65767-z · 2025 · External reference
Structure-based virtual screening and functional validation of potential hit molecules targeting the SARS-CoV-2 main protease
10.3390/biom12121754 · 2022 · External reference
SARS-CoV-2 polyprotein substrate regulates the stepwise M(pro) cleavage reaction
10.1016/j.jbc.2023.104697 · 2023 · External reference
Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
10.1038/s41467-021-21060-3 · 2021 · External reference
An oral SARS-CoV-2 m(pro) inhibitor clinical candidate for the treatment of COVID-19
10.1126/science.abl4784 · 2021 · External reference
Monomeric red fluorescent proteins with a large stokes shift
10.1073/pnas.0914365107 · 2010 · External reference
Application of bioluminescence resonance energy transfer (BRET) for biomolecular interaction studies
10.1002/cbic.200600048 · 2006 · External reference
Super RLuc8: a novel engineered renilla luciferase with a red-shifted spectrum and stable light emission
10.1016/j.enzmictec.2016.09.009 · 2017 · External reference
[Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination]
10.37201/req/002.2022 · 2022 · External reference
Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti–COVID-19 drug design
10.1126/sciadv.abd4596 · 2020 · External reference
SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging
10.1038/s41589-020-00689-z · 2021 · External reference
Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L
10.1126/sciadv.abe0751 · 2020 · External reference
Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2
10.1016/j.chembiol.2021.04.020 · 2021 · External reference
A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum
10.1038/nmeth.2413 · 2013 · External reference
Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance
10.1038/s41467-022-31210-w · 2022 · External reference
Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
10.1038/s41586-020-2601-5 · 2020 · External reference
The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors
10.1038/s41598-021-88630-9 · 2021 · External reference
Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of Nirmatrelvir
10.1002/cpt.2603 · 2022 · External reference
Substrate affinity differentially influences protein kinase C regulation and inhibitor potency
10.1074/jbc.m116.737601 · 2016 · External reference
New chemicals suppressing SARS-CoV-2 replication in cell culture
10.3390/molecules27175732 · 2022 · External reference
Pharmacological characterization of GPCR agonists
2019 · External reference
Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model
10.1126/science.adm9724 · 2024 · External reference
A real-time, plate-based BRET assay for detection of cGMP in primary cells
10.3390/ijms23031908 · 2022 · External reference
Estimating the distance separating fluorescent protein FRET pairs
10.1016/j.ymeth.2013.06.021 · 2014 · External reference
A red-shifted Bioluminescence Resonance Energy Transfer (BRET) biosensing system for rapid measurement of plasmin activity in human plasma
10.1016/j.aca.2019.12.044 · 2020 · External reference
Bioluminescence
10.1146/annurev.cellbio.14.1.197 · 1998 · External reference
Developments in FRET- and BRET-based biosensors
10.3390/mi13101789 · 2022 · External reference
Biochemical and structural insights into SARS-CoV-2 polyprotein processing by Mpro
10.1126/sciadv.add2191 · 2022 · External reference
High-resolution substrate specificity profiling of SARS-CoV-2 M(pro); comparison to SARS-CoV M(pro)
10.1021/acschembio.4c00096 · 2024 · External reference
mBeRFP, an improved large stokes shift red fluorescent protein
2013 · External reference
Translational control of COVID-19 and its therapeutic implication
2022 · External reference
Identification of SARS-CoV-2 PLpro and 3CLpro human proteome substrates using substrate phage display coupled with protein network analysis
10.1016/j.jbc.2023.104831 · 2023 · External reference
Structural basis for replicase polyprotein cleavage and substrate specificity of main protease from SARS-CoV-2
2022 · External reference
Exploring nirmatrelvir derivatives through P2 substituent modifications and warhead innovations targeting the main protease of SARS-CoV-2
10.1002/ardp.70158 · ExternalCitation · doi-reference
The BRET technology and its application to screening assays
10.1002/biot.200700222 · ExternalCitation · doi-reference
Application of bioluminescence resonance energy transfer (BRET) for biomolecular interaction studies
10.1002/cbic.200600048 · ExternalCitation · doi-reference
Innovative randomized phase I study and dosing regimen selection to accelerate and inform pivotal COVID-19 trial of Nirmatrelvir
10.1002/cpt.2603 · ExternalCitation · doi-reference
A red-shifted Bioluminescence Resonance Energy Transfer (BRET) biosensing system for rapid measurement of plasmin activity in human plasma
10.1016/j.aca.2019.12.044 · ExternalCitation · doi-reference
Bioluminescence resonance energy transfer biosensor for measuring activity of a protease secreted by Pseudomonas fluorescens growing in milk
10.1016/j.aca.2023.341401 · ExternalCitation · doi-reference
Dynamics of huntingtin protein interactions in the striatum identifies candidate modifiers of huntington disease
10.1016/j.cels.2022.01.005 · ExternalCitation · doi-reference
Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2
10.1016/j.chembiol.2021.04.020 · ExternalCitation · doi-reference
Investigation of small molecule inhibitors of the SARS-CoV-2 papain-like protease by all-atom microsecond modelling, PELE monte carlo simulations, and in vitro activity inhibition
10.1016/j.cplett.2021.139294 · ExternalCitation · doi-reference
Super RLuc8: a novel engineered renilla luciferase with a red-shifted spectrum and stable light emission
10.1016/j.enzmictec.2016.09.009 · ExternalCitation · doi-reference
A slow but steady nanoLuc: R162A mutation results in a decreased, but stable, nanoLuc activity
10.1016/j.ijbiomac.2024.131864 · ExternalCitation · doi-reference
Improved SARS-CoV-2 main protease high-throughput screening assay using a 5-carboxyfluorescein substrate
10.1016/j.jbc.2022.101739 · ExternalCitation · doi-reference
SARS-CoV-2 polyprotein substrate regulates the stepwise M(pro) cleavage reaction
10.1016/j.jbc.2023.104697 · ExternalCitation · doi-reference
Identification of SARS-CoV-2 PLpro and 3CLpro human proteome substrates using substrate phage display coupled with protein network analysis
10.1016/j.jbc.2023.104831 · ExternalCitation · doi-reference
Kinetic comparison of all eleven viral polyprotein cleavage site processing events by SARS-CoV-2 main protease using a linked protein FRET platform
10.1016/j.jbc.2024.107367 · ExternalCitation · doi-reference
Programmed ribosomal frameshifting in decoding the SARS-CoV genome
10.1016/j.virol.2004.11.038 · ExternalCitation · doi-reference
Estimating the distance separating fluorescent protein FRET pairs
10.1016/j.ymeth.2013.06.021 · ExternalCitation · doi-reference
Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system
10.1016/s1473-3099(23)00118-4 · ExternalCitation · doi-reference
SARS-CoV-2 spike E484K mutation reduces antibody neutralisation
10.1016/s2666-5247(21)00068-9 · ExternalCitation · doi-reference
NanoLuc: a small luciferase is brightening up the field of bioluminescence
10.1021/acs.bioconjchem.6b00112 · ExternalCitation · doi-reference
Discovery of SARS-CoV-2 papain-like protease inhibitors through a combination of high-throughput screening and a FlipGFP-Based reporter assay
10.1021/acscentsci.1c00519 · ExternalCitation · doi-reference
High-resolution substrate specificity profiling of SARS-CoV-2 M(pro); comparison to SARS-CoV M(pro)
10.1021/acschembio.4c00096 · ExternalCitation · doi-reference
Identification of human host substrates of the SARS-CoV-2 M(pro) and PL(pro) using subtiligase N-Terminomics
10.1021/acsinfecdis.2c00458 · ExternalCitation · doi-reference
Bright bioluminescent BRET sensor proteins for measuring intracellular caspase activity
10.1021/acssensors.7b00239 · ExternalCitation · doi-reference
Creation of artificial luciferases for bioassays
10.1021/bc400411h · ExternalCitation · doi-reference
Papain-like protease 2 (PLP2) from severe acute respiratory syndrome coronavirus (SARS-CoV): expression, purification, characterization, and inhibition
10.1021/bi0504761 · ExternalCitation · doi-reference
A bright cyan-excitable Orange fluorescent protein facilitates dual-emission microscopy and enhances bioluminescence imaging in vivo
10.1038/nbt.3550 · ExternalCitation · doi-reference
A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum
10.1038/nmeth.2413 · ExternalCitation · doi-reference
mScarlet: a bright monomeric red fluorescent protein for cellular imaging
10.1038/nmeth.4074 · ExternalCitation · doi-reference
Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
10.1038/s41422-020-0356-z · ExternalCitation · doi-reference
Both boceprevir and GC376 efficaciously inhibit SARS-CoV-2 by targeting its main protease
10.1038/s41467-020-18233-x · ExternalCitation · doi-reference
The complex structure of GRL0617 and SARS-CoV-2 PLpro reveals a hot spot for antiviral drug discovery
10.1038/s41467-020-20718-8 · ExternalCitation · doi-reference
Structure of papain-like protease from SARS-CoV-2 and its complexes with non-covalent inhibitors
10.1038/s41467-021-21060-3 · ExternalCitation · doi-reference
The oral protease inhibitor (PF-07321332) protects Syrian hamsters against infection with SARS-CoV-2 variants of concern
10.1038/s41467-022-28354-0 · ExternalCitation · doi-reference
Defining the substrate envelope of SARS-CoV-2 main protease to predict and avoid drug resistance
10.1038/s41467-022-31210-w · ExternalCitation · doi-reference
X-ray crystallographic characterization of the SARS-CoV-2 main protease polyprotein cleavage sites essential for viral processing and maturation
10.1038/s41467-022-32854-4 · ExternalCitation · doi-reference
Discovery of orally bioavailable SARS-CoV-2 papain-like protease inhibitor as a potential treatment for COVID-19
10.1038/s41467-024-54462-0 · ExternalCitation · doi-reference
Distal protein-protein interactions contribute to nirmatrelvir resistance
10.1038/s41467-025-56651-x · ExternalCitation · doi-reference
A SARS-CoV-2 Mpro mutation conferring ensitrelvir resistance paradoxically increases nirmatrelvir susceptibility
10.1038/s41467-025-65767-z · ExternalCitation · doi-reference
Papain-like protease regulates SARS-CoV-2 viral spread and innate immunity
10.1038/s41586-020-2601-5 · ExternalCitation · doi-reference
The coding capacity of SARS-CoV-2
10.1038/s41586-020-2739-1 · ExternalCitation · doi-reference
SARS-CoV-2 Mpro inhibitors and activity-based probes for patient-sample imaging
10.1038/s41589-020-00689-z · ExternalCitation · doi-reference
The dimer-monomer equilibrium of SARS-CoV-2 main protease is affected by small molecule inhibitors
10.1038/s41598-021-88630-9 · ExternalCitation · doi-reference
Allostery in homodimeric SARS-CoV-2 main protease
10.1038/s42003-024-07138-w · ExternalCitation · doi-reference
A genetically encoded BRET-based SARS-CoV-2 Mpro protease activity sensor
10.1038/s42004-022-00731-2 · ExternalCitation · doi-reference
Coevolving residues distant from the ligand binding site are involved in GAF domain function
10.1038/s42004-025-01447-9 · ExternalCitation · doi-reference
Discovery of SARS-CoV-2 M(pro) peptide inhibitors from modelling substrate and ligand binding
10.1039/d1sc03628a · ExternalCitation · doi-reference
Monomeric red fluorescent proteins with a large stokes shift
10.1073/pnas.0914365107 · ExternalCitation · doi-reference
Substrate affinity differentially influences protein kinase C regulation and inhibitor potency
10.1074/jbc.m116.737601 · ExternalCitation · doi-reference
Use of a cAMP BRET sensor to characterize a novel regulation of cAMP by the sphingosine 1-phosphate/G13 pathway
10.1074/jbc.m609695200 · ExternalCitation · doi-reference
Impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant-associated receptor binding domain (RBD) mutations on the susceptibility to serum antibodies elicited by coronavirus disease 2019 (COVID-19) infection or vaccination
10.1093/cid/ciab656 · ExternalCitation · doi-reference
Residues on the dimer interface of SARS coronavirus 3C-like protease: dimer stability characterization and enzyme catalytic activity analysis
10.1093/jb/mvm246 · ExternalCitation · doi-reference
Consensus guided mutagenesis of renilla luciferase yields enhanced stability and light output
10.1093/protein/gzl023 · ExternalCitation · doi-reference
Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: a framework for anti–COVID-19 drug design
10.1126/sciadv.abd4596 · ExternalCitation · doi-reference
Structure and inhibition of the SARS-CoV-2 main protease reveal strategy for developing dual inhibitors against Mpro and cathepsin L
10.1126/sciadv.abe0751 · ExternalCitation · doi-reference
Biochemical and structural insights into SARS-CoV-2 polyprotein processing by Mpro
10.1126/sciadv.add2191 · ExternalCitation · doi-reference
Discovery of SARS-CoV-2 papain-like protease (PLpro) inhibitors with efficacy in a murine infection model
10.1126/sciadv.ado4288 · ExternalCitation · doi-reference
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
10.1126/science.abb4489 · ExternalCitation · doi-reference
An oral SARS-CoV-2 m(pro) inhibitor clinical candidate for the treatment of COVID-19
10.1126/science.abl4784 · ExternalCitation · doi-reference
Design of a SARS-CoV-2 papain-like protease inhibitor with antiviral efficacy in a mouse model
10.1126/science.adm9724 · ExternalCitation · doi-reference
Kinetic characterization and inhibitor screening for the proteases leading to identification of drugs against SARS-CoV-2
10.1128/aac.02577-20 · ExternalCitation · doi-reference
Development of a fluorescence-based, high-throughput SARS-CoV-2 3CLpro reporter assay
10.1128/jvi.01265-20 · ExternalCitation · doi-reference
Bioluminescence
10.1146/annurev.cellbio.14.1.197 · ExternalCitation · doi-reference
Paxlovid: mechanism of action, synthesis, and in Silico Study
10.1155/2022/7341493 · ExternalCitation · doi-reference
Development of conformational BRET biosensors that monitor ezrin, radixin and moesin activation in real time
10.1242/jcs.255307 · ExternalCitation · doi-reference
Evolution of BRET biosensors from live cell to tissue-scale in vivo imaging
10.3389/fendo.2013.00131 · ExternalCitation · doi-reference
Structure-based virtual screening and functional validation of potential hit molecules targeting the SARS-CoV-2 main protease
10.3390/biom12121754 · ExternalCitation · doi-reference
Intracellular ionic strength sensing using NanoLuc
10.3390/ijms22020677 · ExternalCitation · doi-reference
A real-time, plate-based BRET assay for detection of cGMP in primary cells
10.3390/ijms23031908 · ExternalCitation · doi-reference
Developments in FRET- and BRET-based biosensors
10.3390/mi13101789 · ExternalCitation · doi-reference
New chemicals suppressing SARS-CoV-2 replication in cell culture
10.3390/molecules27175732 · ExternalCitation · doi-reference
[Nirmatrelvir plus ritonavir (Paxlovid) a potent SARS-CoV-2 3CLpro protease inhibitor combination]
10.37201/req/002.2022 · ExternalCitation · doi-reference
A genetically encoded IL-1β bioluminescence resonance energy transfer sensor to monitor inflammasome activity
10.4049/jimmunol.1201349 · ExternalCitation · doi-reference
